Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 14/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.44 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28378160 | 0.85 | CD38 (0.47) | CD38CYP3A4KCNH2STIM1ORAI1 | |
| SCHEMBL127089 | 0.85 | POLB (0.46) | CD38 | |
| SCHEMBL22622601 | 0.82 | CD38 (0.45) | CD38CYP3A4KCNH2KLKB1STIM1 | |
| SCHEMBL8772056 | 0.79 | P2RX7 (0.45) | CD38CYP3A4KCNH2STIM1ORAI1 | |
| SCHEMBL21135383 | 0.79 | POLB (0.49) | CD38CYP3A4KCNH2KLKB1STIM1 | |
| SCHEMBL29592899 | 0.79 | POLB (0.49) | CD38CYP3A4KCNH2KLKB1STIM1 | |
| SCHEMBL21136458 | 0.78 | HTT (0.45) | CD38CYP3A4KCNH2KLKB1STIM1 | |
| SCHEMBL22622587 | 0.76 | CD38 (0.41) | CD38CYP3A4KCNH2KLKB1STIM1 | |
| SCHEMBL24094008 | 0.76 | HPGD (0.52) | CD38KLKB1 | |
| SCHEMBL4586644 | 0.76 | EPHX2 (0.57) | CD38CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-03-09 | — | — | US | claimed |
| CN-111333548-B | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2022-04-26 | — | — | CN | claimed |
| WO-2021130776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-07-01 | — | — | WO | claimed |
| CN-111333548-A | Preparation method of 1- (2-fluoro-6- (trifluoromethyl) benzyl) urea | 江苏海悦康医药科技有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-119552123-A | Preparation method of oxaagoli sodium and intermediate thereof | 哈药集团技术中心 | 2025-03-04 | — | — | CN | disclosed |
| CN-112694445-B | Purification method of oxaagole sodium intermediate | 成都倍特药业股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116425684-A | Synthesis method of oxaagole sodium intermediate | 安徽联创生物医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-111333587-B | Substituted pyrimidine-2, 4 (1H, 3H) -dione derivatives and uses thereof | 东莞市东阳光新药研发有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-03-09 | — | — | US | disclosed |
| CN-110498770-B | Method for preparing intermediate of oxaagolide | 上海医药工业研究院 | 2023-02-17 | — | — | CN | disclosed |
| CN-110498771-B | Method for preparing intermediate of pergolide | 上海医药工业研究院 | 2023-02-17 | — | — | CN | disclosed |
| US-11542239-B2 | Elagolix sodium compositions and processes | ABBVIE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-7015226-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| WO-2005113516-A1 | URACIL-TYPE GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050043338-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (CA) | 2005-02-17 | — | — | US | disclosed |
| US-20050038056-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005007633-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007165-A1 | PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007164-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038056-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD38 246/4885CYP3A4 1434/4885KCNH2 1324/4885 |
| US-11542239-B2 | Elagolix sodium compositions and processes | ELOVL5, ELOC, ELOVL3 | CD38 1221/4885CYP3A4 2754/4885KCNH2 4603/4885 |
| US-20050043338-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD38 287/4885CYP3A4 1232/4885KCNH2 1444/4885 |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD38 245/4885CYP3A4 1565/4885KCNH2 1272/4885 |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | BPNT1, GABRA6, GABRA1 | CD38 3849/4885CYP3A4 63/4885KCNH2 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.